DESTINY: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05334368

Collaborator

(none)

120

Enrollment

Arms

36.6

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.

The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.

Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.

Condition or Disease	Intervention/Treatment	Phase
Hypereosinophilic Syndrome	Drug: Depemokimab Other: Placebo	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study.This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

This will be a double-blind study with respect to allocation of depemokimab or placebo to participants. All site staff, participants, and investigator will be blinded.

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

Anticipated Study Start Date :

May 11, 2022

Anticipated Primary Completion Date :

May 2, 2025

Anticipated Study Completion Date :

May 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Depemokimab All participants in this arm will receive depemokimab.	Drug: Depemokimab Depemokimab will be administered.
Placebo Comparator: Placebo All participants in this arm will receive placebo.	Other: Placebo Matching placebo will be administered.

Arm

Intervention/Treatment

Experimental: Depemokimab

All participants in this arm will receive depemokimab.

Drug: Depemokimab

Depemokimab will be administered.

Placebo Comparator: Placebo

All participants in this arm will receive placebo.

Other: Placebo

Matching placebo will be administered.

Outcome Measures

Primary Outcome Measures

Frequency of HES flares [Up to 52 weeks]
A HES flare is defined as either: a HES-related clinical manifestation based on a physician documented change in clinical signs or symptoms resulting in the need for the following : An increase in the maintenance systemic corticosteroid dose by at least 10 mg/day (prednisone/prednisolone equivalent) for at least 5 days, and/or an increase in or addition of any cytotoxic and/or immunosuppressive HES therapy. OR 2 or more courses of blinded active oral corticosteroid (OCS) during the intervention period. The frequency of HES flares will be calculated for each participant as the number of unique starting dates for HES flares.

Secondary Outcome Measures

Time to first HES flare [Up to 52 weeks]
The time to first HES flare will be calculated from the date of first dose of study intervention and the start date of the HES flare. Time to the first HES flare will be assessed and reported in days.
Number of participants with at least one HES flare during the 52-week study intervention period [Up to 52 weeks]
Change from Baseline to Week 52 in weekly average score of Brief Fatigue Inventory (BFI) item 3 (worst fatigue in last 24 hours) [Baseline and up to Week 52]
The BFI is a tool developed for the rapid assessment of fatigue severity for use in both clinical Screening and clinical trials. The BFI has 9 items. The participant should rate their average and worst fatigue levels over the previous 24 hours using a numeric rating scale anchored with 0 (no fatigue/interference) and 10 (as bad as you can imagine/completely interferes) numeric rating scales

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Participants who are greater than or equal (>=) 40 kilogram (kg) at Screening Visit 1.
Participants who have a documented diagnosis of HES prior to Visit 2.
A history of 2 or more HES flares within the past 12 months prior to Visit 1.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: a) woman of non-childbearing potential (WONCBP) Or b) woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<) 1 percentage (%).
Capable of giving signed informed consent.

Exclusion Criteria:

Participants with HES disease manifestations which in the opinion of the investigator may put the participant at unacceptable risk from study participation or confound interpretation of efficacy or safety data.
Participants with chronic or ongoing active infections requiring systemic treatment or a pre-existing parasitic infestation within 6 months prior to Visit 1.
Participants with a known immunodeficiency (e.g., Human Immunodeficiency Virus [HIV]), other than that explained by the use of OCS or other therapy taken for HES.
Participants with a history of or current lymphoma.
Participants with current malignancy or previous history of cancer in remission for less than 5 years prior to Visit 1. Participants that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded.
Participants with a haematologic malignancy with hypereosinophilia in which HES is not the primary diagnosis, e.g., chronic myeloid leukaemia, myelodysplastic syndrome, chronic eosinophilic leukaemia-not otherwise specified.
Cirrhosis or current unstable liver or biliary disease per investigator assessment.
Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.
Participants with current diagnosis of vasculitis.
Hypereosinophila with no clinical symptoms and/or proof of organ dysfunction.
Clinical diagnosis of Eosinophilic granulomatosis with polyangiitis (EGPA).
Participants with an allergy/ intolerance to a monoclonal antibody or biologic, or any of the excipients of the investigational product.
Participants who have a previous documented failure with anti-interleukin (IL)-5/5R therapy.
Participants who have received monoclonal antibodies (mAb) within 30 days or 5 half-lives, whichever is longer, prior to Visit 1.
Participants who test positive for the FIP1L1-PDGFRα fusion gene.
QT interval corrected for heart rate according to Fridericia's formula (QTcF) ≥450 milliseconds (msec) or QTcF ≥480 msec for participants with Bundle Branch Block at Screening Visit 1.
Participants who are not responsive to OCS based on clinical response or blood eosinophil counts in the opinion of the Investigator.
Participants who are pregnant or breastfeeding.